Actinium Pharmaceuticals, Inc. , a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Mr. Sandesh Seth, Executive Chairman of Actinium, and other members of the management team will be attending the Canaccord Genuity Rare Disease and Biopharma One-on-One Day on Tuesday, February 3, 2015. Members of the investment community who are interested in meeting with management should contact Evan Smith, CFA of Actinium Pharmaceuticals at 840-5442 or esmith@actiniumpharma.com .
http://ift.tt/18tSi9X
http://ift.tt/18tSi9X
No comments:
Post a Comment